A study of the correlation between gait abnormalities, activity monitoring parameters, CMTPedS and a biomarker in children with Charcot-Marie-Tooth disease.

by | Mar 1, 2022 | 0 comments

A study of the correlation between gait abnormalities, activity monitoring parameters, CMTPedS and a biomarker in children with Charcot-Marie-Tooth disease.

STUDY INVESTIGATORS: SYLVIA OUNPUU MSC, GUYLA ACSADI, MD, PHD, AND KRISTAN PIERZ, MD. 

BACKGROUND:

The overall goal of our research is to improve treatment outcomes that address gait dysfunction for children with Charcot-Marie-Tooth disease (CMT), since gait is one of the most important elements for quality of life for persons with CMT. To achieve this goal, a better understanding of the relationship between gait function, activity levels in the community and how these measures change over time is important. Identifying biomarkers for disease state and progression is also important for determining the efficacy of emerging new treatments for which the goal is to improve walking. Because of the generous funding by the Penn Medicine Orphan Disease Center we were able to add an additional 15 patient tests (some repeat and some new) to our existing study cohort which currently includes 68 patients.

RESULTS:

A preliminary analysis with a focus on the sagittal plane ankle motion during walking from a cohort of 45 patients with CMT1 and 2 showed differences in changes with age depending on CMT type. In children with CMT1, peak dorsiflexion in terminal stance (TST) increased with age through 13 years (p=0.004) and then plateaued in the normal range (p=0.73). The peak ankle angle in mid-swing and TST were closely related (p<0.001) following a similar change with age. In children with CMT2, there was no significant change in peak dorsiflexion in TST with age (p=0.19) and peak ankle angle in mid-swing was not related to peak dorsiflexion in TST (p=0.43) or age (p=0.88). There were also no consistent trends with age for individual patients with multiple tests.

SUMMARY:

Patients with CMT1 show beneficial changes in ankle function during both the stance and swing phases of gait with age, reaching a plateau around age 13 years. Patients with CMT2, however, do not show any systematic changes in ankle function during gait with age. Future studies with more repeat assessments for individual patients are needed to gain further understanding of gait changes with age in children with CMT. The heterogeneity of gait and joint level impairments point to the importance of a better understand the disease severity and progression for each individual. This knowledge will enable more informed treatment decisions and better understanding of treatment outcomes in the context of disease progression.

HNF was pleased to fund this promising research at the prestigious Connecticut Children’s Gait Lab. The project was overseen by Director of Research and Education, Sylvia Ounpuu, MSC, and Gyula Acsadi, MD, PhD, Division Head of Neurology. Both investigators are a part of the Inherited Neuropathy Consortium, as is HNF.

Learn more on this topic

Related Blog Posts

Global Registry For Inherited Neuropathies: Your Questions Answered

Global Registry For Inherited Neuropathies: Your Questions Answered

Why are we asking you to join our registry? It’s simple. Without you, researchers won’t have the essential patient information to develop the drugs, gene therapy, and clinical trials for Charcot-Marie-Tooth and other inherited neuropathies.
This is why the Hereditary Neuropathy Foundation (HNF) created the Global Registry for Inherited Neuropathies (GRIN). The registry collects the historical, clinical, and genetic information on patients diagnosed with the various forms of inherited neuropathies to help advance therapy development for these debilitating disorders. We understand there may be some hesitation joining our registry. To help mitigate any concerns, we’ve have the answers to your most common questions.

Pharnext Announces Pleotherapy Proof of Concept in Charcot-Marie-Tooth Disease Type 1A

Pharnext Announces Pleotherapy Proof of Concept in Charcot-Marie-Tooth Disease Type 1A

PARIS, December 18th, 2014 – Pharnext SAS today announced the proof of concept of its pleotherapy research and development approach based on a proprietary network pharmacology platform that identifies synergic combinations of drugs already approved for other diseases. Indeed, Pharnext’s lead pleodrug, PXT-3003, has shown positive results both in preclinical and Phase 2 clinical studies published today in the Orphanet Journal of Rare Diseases.

Hot off the press

Some recent papers on Charcot-Marie-Tooth (CMT) disease go to show that we are steadily and impressively peeling back the complexity of the biology even though it is a relatively common rare disease with several thousand publications on it.

Join the conversation

Leave a Comment

0 Comments

Submit a Comment

Your email address will not be published. Required fields are marked *

Newsletter

Join for notifications on events, campaigns, & news